tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
BDRX
Biodexa Pharmaceuticals
Stock Analysis
Technical Analysis
Chart
Earnings
Dividends
Ownership
Financials
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Holding BDRX?
Track your performance easily
Link Broker

Biodexa Pharmaceuticals (BDRX) Income Statement

417 Followers

Biodexa Pharmaceuticals Income Statement

Last quarter (Q2 2022), Biodexa Pharmaceuticals's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, Biodexa Pharmaceuticals's net income was £―. See Biodexa Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
-£ 578.00K£ 343.00K£ 312.00K£ 149.00K£ 989.00K
Cost of Revenue
-£ 4.65M£ 6.07M£ 7.84M£ 9.36M£ 8.33M
Gross Profit
-£ -4.08M£ -5.72M£ -7.53M£ -9.21M£ -7.34M
Operating Expense
-£ 2.92M£ 4.95M£ 3.79M£ 2.60M£ 4.44M
Operating Income
-£ -7.00M£ -10.67M£ -11.32M£ -11.81M£ -11.78M
Net Non Operating Interest Income Expense
-£ 44.00K£ 33.00K£ 89.00K£ 585.00K£ 94.00K
Other Income Expense
------
Pretax Income
-£ -6.11M£ -23.47M£ -10.92M£ -12.40M£ -12.97M
Tax Provision
-£ -646.00K£ -1.28M£ -1.78M£ -2.03M£ -1.26M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ -5.46M£ -22.19M£ -10.09M£ -15.03M£ -16.06M
Basic EPS
-£ -1.40£ -10.40£ -220.00£ -98.60£ -122.20
Diluted EPS
-£ -1.40£ -10.40£ -220.00£ -98.60£ -122.20
Basic Average Shares
-£ 4.03M£ 2.14M£ 916.53K£ 155.10K£ 130.21K
Diluted Average Shares
-£ 4.03M£ 2.14M£ 45.83K£ 155.10K£ 130.21K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-£ -7.58M£ -11.01M£ -11.63M£ -11.96M£ -12.77M
Net Income From Continuing And Discontinued Operation
-£ -5.46M£ -22.19M£ -10.09M£ -15.03M£ -16.06M
Normalized Income
-£ -6.75M£ 384.00K£ -9.61M£ -12.40M£ -11.47M
Interest Expense
-£ 44.00K£ 34.00K£ 97.00K--
EBIT
-£ -6.06M£ -23.44M£ -11.77M£ -9.78M£ -11.60M
EBITDA
-£ -5.66M£ -22.22M£ -11.77M£ -9.78M£ -11.60M
Currency in GBP

Biodexa Pharmaceuticals Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis
Subscribe NowSee Plans & Pricing